These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24820799)

  • 1. [Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Mockenhaupt M
    Hautarzt; 2014 May; 65(5):415-23. PubMed ID: 24820799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acute life-threatening drug reactions of the skin].
    Mockenhaupt M
    Hautarzt; 2018 May; 69(5):364-375. PubMed ID: 29721625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Severe skin reactions due to new medications].
    Mockenhaupt M; Paulmann M
    Hautarzt; 2018 Apr; 69(4):278-289. PubMed ID: 29568997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Severe cutaneous drug reactions in children].
    Mockenhaupt M
    Hautarzt; 2017 Oct; 68(10):803-814. PubMed ID: 28932875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Ferrandiz-Pulido C; Garcia-Patos V
    Arch Dis Child; 2013 Dec; 98(12):998-1003. PubMed ID: 23873883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN.
    Ramien ML; Mansour D; Shear NH
    Paediatr Drugs; 2022 Jul; 24(4):307-319. PubMed ID: 35676614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy.
    Heuer R; Paulmann M; Annecke T; Behr B; Boch K; Boos AM; Brockow K; French LE; Gille J; Gundlach V; Hartmann B; Höger P; Hofmann SC; Klein T; Lehnhardt M; Liß Y; Maier P; Mandel P; Marathovouniotis N; Marlok F; Mittelviefhaus H; Pleyer U; Pradeau M; Rall K; Rieg S; Rittner H; Sander F; Schnitzler S; Schut C; Stolle A; Vorobyev A; Wedi B; Weiss J; Zepp M; Ziemer M; Mockenhaupt M; Nast A
    J Dtsch Dermatol Ges; 2024 Oct; 22(10):1448-1466. PubMed ID: 39314017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Fritsch PO; Sidoroff A
    Am J Clin Dermatol; 2000; 1(6):349-60. PubMed ID: 11702611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
    Halevy S
    Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stevens-Johnson Syndrome: A Challenging Diagnosis.
    Davis WD; Schafer PA
    Adv Emerg Nurs J; 2018; 40(3):176-182. PubMed ID: 30059372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
    Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis.
    van Nispen C; Long B; Koyfman A
    Am J Emerg Med; 2024 Jul; 81():16-22. PubMed ID: 38631147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute blistering diseases on the burn ward: Beyond Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Richer V; Bouffard D; Bélisle A; Duranceau L; Perreault I; Provost N
    Burns; 2013 Sep; 39(6):1290-6. PubMed ID: 23597847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
    Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F
    N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
    Sane SP; Bhatt AD
    J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
    Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness.
    Lim VM; Do A; Berger TG; Nguyen AH; DeWeese J; Malone JD; Jordan K; Hom F; Tuffanelli L; Fillari P; Siu S; Grossman R
    Burns; 2016 Jun; 42(4):836-43. PubMed ID: 26847613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.